Helix BioPharma Expands Oncology Portfolio with Strategic Acquisition

Helix BioPharma ( (TSE:HBP) ) just unveiled an update.

Helix BioPharma has acquired LEUMUNA™ and GEMCEDA™ from Laevoroc Group, enhancing its oncology portfolio with these pre-IND candidates. This strategic acquisition is expected to strengthen Helix’s position in cancer treatment, offering new therapeutic options for leukemia and other cancers, while also expanding its board of directors with the appointment of Dr. Thomas Mehrling.

Spark’s Take on TSE:HBP Stock

According to Spark, TipRanks’ AI Analyst, TSE:HBP is a Underperform.

Helix BioPharma faces significant financial challenges with no revenue and continuous losses, resulting in a low financial performance score. Weak market momentum and poor valuation metrics further dampen the stock’s attractiveness. Recent corporate events provide some strategic hope, but are not enough to overcome the fundamental financial issues.

To see Spark’s full report on TSE:HBP stock, click here.

More about Helix BioPharma

Helix BioPharma Corp. is a clinical-stage oncology company focused on developing treatments for hard-to-treat cancers. It operates in the biopharmaceutical industry, with a market focus on innovative cancer therapies.

Average Trading Volume: 3,748

Technical Sentiment Signal: Sell

Current Market Cap: C$50.9M

For detailed information about HBP stock, go to TipRanks’ Stock Analysis page.